Homepage

Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries

Screening Compounds Building blocks

Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls

Company News & Media Contact us For suppliers Trends in discovery compounds

Homepage > Company > Media > Pharma News > 2024 > Lexicon Loses FDA Adcomm Vote on Insulin Adjunct for Patients With Type 1 Diabetes

Lexicon Loses FDA Adcomm Vote on Insulin Adjunct for Patients With Type 1 Diabetes

Lexicon Loses FDA Adcomm Vote on Insulin Adjunct for Patients With Type 1 Diabetes

Read also

US court upholds Avadel’s narcolepsy drug approval amid exclusivity battle

US court upholds Avadel’s narcolepsy drug approval amid exclusivity battle

The US District Court upholds the FDA’s approval of Avadel’s Lumryz, dismissing Jazz’s challenge over market exclusivity for its own drug. Avadel and Jazz Pharmaceutical’s drugs’ treat narco...

FDA-approved drug for ulcerative colitis also effective for Crohn's

FDA-approved drug for ulcerative colitis also effective for Crohn's

Mirikizumab is a drug currently approved by the Food and Drug Administration (FDA) for the treatment of ulcerative colitis. Researchers estimate about 10 million people around the w...

FDA Approves McGuff Pharmaceuticals Facility in Santa Ana, CA

FDA Approves McGuff Pharmaceuticals Facility in Santa Ana, CA

McGuff Pharmaceuticals, Inc. (MPI) has received FDA approval of its cGMP facility in Santa Ana, CA. This facility is a state-of-the-art, 86,000-sq.-ft. sterile fill-and-finish pharmaceutical m...

OKI-219

OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium